Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis

Science Translational Medicine

Volumn 4, Issue 145, 2012, Pages

  Grant, Jacqueline L ^a,b   Ghosn, Eliver Eid Bou ^b   Axtell, Robert C ^a   Herges, Katja ^a   Kuipers, Hedwich F ^a   Woodling, Nathan S ^a,b   Andreasson, Katrin ^a   Herzenberg, Leonard A ^b   Herzenberg, Leonore A ^b   Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CD19 ANTIGEN; CD4 ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; L SELECTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR FOXP3;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL COUNT; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; LYMPHOID TISSUE; MOUSE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; UPREGULATION;

AMYLOID BETA-PEPTIDES; ANIMALS; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLOW CYTOMETRY; INFLAMMATION; MICE; MICE, INBRED C57BL; PARALYSIS; TH1 CELLS; TH17 CELLS;

EID: 84864553199     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004145     Document Type: Article

References (60)

1. G. M. Shankar, S. Li, T. H. Mehta, A. Garcia-Munoz, N. E. Shepardson, I. Smith, F. M. Brett, M. A. Farrell, M. J. Rowan, C. A. Lemere, C. M. Regan, D. M. Walsh, B. L. Sabatini, D. J. Selkoe, Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842 (2008).
2. M. Citron, T. Oltersdorf, C. Haass, L. McConlogue, A. Y. Hung, P. Seubert, C. Vigo-Pelfrey, I. Lieberburg, D. J. Selkoe, Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360, 672-674 (1992).
3. S. Lesné, M. T. Koh, L. Kotilinek, R. Kayed, C. G. Glabe, A. Yang, M. Gallagher, K. H. Ashe, A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352 -357 (2006).
4. D.M. Walsh, I. Klyubin, J. V. Fadeeva, W. K. Cullen, R.Anwyl, M. S. Wolfe, M. J. Rowan, D. J. Selkoe, Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
5. D. L. Price, S. S. Sisodia, Mutant genes in familial Alzheimer 's disease and transgenic models. Annu. Rev. Neurosci. 21, 479-505 (1998).
6. A. R. Simard, D. Soulet, G. Gowing, J. P. Julien, S. Rivest, Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489-502 (2006).
7. S. Itagaki, P. L. McGeer, H. Akiyama, S. Zhu, D. Selkoe, Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 24, 173-182 (1989).
8. J. Rogers, N. R. Cooper, S. Webster, J. Schultz, P. L. McGeer, S. D. Styren, W. H. Civin, L. Brachova, B. Bradt, P. Ward, I. Lieberburg, Complement activation by β-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 89, 10016-10020 (1992).
9. T. Wyss-Coray, Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? Nat. Med. 12, 1005-1015 (2006).
10. W. S. Griffin, L. C. Stanley, C. Ling, L. White, V. MacLeod, L. J. Perrot, C. L. White III, C. Araoz, Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 86, 7611-7615 (1989).
11. A. Monsonego, H. L. Weiner, Immunotherapeutic approaches to Alzheimer's disease. Science 302, 834-838 (2003).
12. J. Hardy, D. J. Selkoe, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
13. H. L. Weiner, D. Frenkel, Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. 6, 404-416 (2006).
14. C. Haass, M. G. Schlossmacher, A. Y. Hung, C. Vigo-Pelfrey, A. Mellon, B. L. Ostaszewski, I. Lieberburg, E. H. Koo, D. Schenk, D. B. Teplow, D. J. Selkoe, Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359, 322-325 (1992).
15. G. Thinakaran, E. H. Koo, Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283, 29615-29619 (2008).
16. K. Uryu, X.H. Chen, D. Martinez, K. D. Browne, V. E. Johnson,D. I. Graham, V.M. Lee, J. Q. Trojanowski, D. H. Smith, Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp. Neurol. 208, 185-192 (2007).
17. R. B. DeMattos, K. R. Bales, D. J. Cummins, S. M. Paul, D. M. Holtzman, Brain to plasma amyloid-β efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267 (2002).
18. K. Yaffe, A. Weston, N. R. Graff-Radford, S. Satterfield, E. M. Simonsick, S. G. Younkin, L. H. Younkin, L. Kuller, H. N. Ayonayon, J. Ding, T. B. Harris, Association of plasma β-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305, 261-266 (2011).
19. E. M. Frohman, M. K. Racke, C. S. Raine, Multiple sclerosis - The plaque and its pathogenesis. N. Engl. J. Med. 354, 942-955 (2006).
20. B. D. Trapp, J. Peterson, R. M. Ransohoff, R. Rudick, S. Mörk, L. Bö, Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998).
21. B. Ferguson, M. K. Matyszak, M. M. Esiri, V. H. Perry, Axonal damage in acute multiple sclerosis lesions. Brain 120 (Pt. 3), 393-399 (1997).
22. S. S. Ousman, B. H. Tomooka, J. M. van Noort, E. F. Wawrousek, K. C. O'Connor, D. A. Hafler, R. A. Sobel, W. H. Robinson, L. Steinman, Protective and therapeutic role for αB-crystallin in autoimmune demyelination. Nature 448, 474-479 (2007).
23. M. H. Han, S. I. Hwang, D. B. Roy, D. H. Lundgren, J. V. Price, S. S. Ousman, G. H. Fernald, B. Gerlitz, W. H. Robinson, S. E. Baranzini, B. W. Grinnell, C. S. Raine, R. A. Sobel, D. K. Han, L. Steinman, Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451, 1076-1081 (2008).
24. S. S. Zamvil, L. Steinman, The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8, 579-621 (1990).
25. L. Steinman, Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nat. Rev. Drug Discov. 4, 510-518 (2005).
26. J. Chun, H. P. Hartung, Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 33, 91-101 (2010).
27. R. Veerhuis, I. Janssen, C. E. Hack, P. Eikelenboom, Early complement components in Alzheimer's disease brains. Acta Neuropathol. 91, 53-60 (1996).
28. P. L. McGeer, S. Itagaki, E. G. McGeer, Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 76, 550-557 (1988).
29. T. Togo, H. Akiyama, E. Iseki, H. Kondo, K. Ikeda, M. Kato, T. Oda, K. Tsuchiya, K. Kosaka, Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J. Neuroimmunol. 124, 83-92 (2002).
30. A. Monsonego, V. Zota, A. Karni, J. I. Krieger, A. Bar-Or, G. Bitan, A. E. Budson, R. Sperling, D. J. Selkoe, H. L. Weiner, Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112, 415-422 (2003).
31. R. C. Axtell, B. A. de Jong, K. Boniface, L. F. van der Voort, R. Bhat, P. De Sarno, R. Naves, M. Han, F. Zhong, J. G. Castellanos, R. Mair, A. Christakos, I. Kolkowitz, L. Katz, J. Killestein, C. H. Polman, R. de Waal Malefyt, L. Steinman, C. Raman, T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16, 406-412 (2010).
32. P. Miossec, T. Korn, V. K. Kuchroo, Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361, 888-898 (2009).
33. L. Steinman, A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13, 139-145 (2007).
34. R. Pedotti, D. Mitchell, J. Wedemeyer, M. Karpuj, D. Chabas, E. M. Hattab, M. Tsai, S. J. Galli, L. Steinman, An unexpected version of horror autotoxicus: Anaphylactic shock to a self-peptide. Nat. Immunol. 2, 216-222 (2001).
35. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games, P. Seubert, Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
36. D. Frenkel, R. Maron, D. S. Burt, H. L. Weiner, Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest. 115, 2423-2433 (2005).
37. F. Bard, C. Cannon, R. Barbour, R. L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, I. Lieberburg, R. Motter, M. Nguyen, F. Soriano, N. Vasquez, K. Weiss, B. Welch, P. Seubert, D. Schenk, T. Yednock, Peripherally administered antibodies against amyloid b- peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916 -919 (2000).
38. J. A. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, R. O. Weller, Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case report. Nat. Med. 9, 448-452 (2003).
39. M. El-behi, A. Rostami, B. Ciric, Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J. Neuroimmune Pharmacol. 5, 189-197 (2010).
40. I. M. Stromnes, J. M. Goverman, Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 1, 1810-1819 (2006).
41. E. M. Frohman, T. Eagar, N. Monson, O. Stuve, N. Karandikar, Immunologic mechanisms of multiple sclerosis. Neuroimaging Clin. N. Am. 18, 577-588 (2008).
42. M. K. Waldor, S. Sriram, R. Hardy, L. A. Herzenberg, L. A. Herzenberg, L. Lanier,M. Lim, L. Steinman, Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science 227, 415-417 (1985).
43. K. W. Moore, R. deWaal Malefyt, R. L. Coffman, A. O'Garra, Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683-765 (2001).
44. J. M. Lund, L. Hsing, T. T. Pham, A. Y. Rudensky, Coordination of early protective immunity to viral infection by regulatory T cells. Science 320, 1220-1224 (2008).
45. L. Passerini, S. Di Nunzio, S. Gregori, E. Gambineri, M. Cecconi, M. G. Seidel, G. Cazzola, L. Perroni, A. Tommasini, S. Vignola, L. Guidi, M. G. Roncarolo, R. Bacchetta, Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. Eur. J. Immunol. 41, 1120-1131 (2011).
46. J. T. Jarrett, P. T. Lansbury Jr., Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058 (1993).
47. N. Zamzami, P. Marchetti, M. Castedo, C. Zanin, J. L. Vayssière, P. X. Petit, G. Kroemer, Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med. 181, 1661-1672 (1995).
48. E. E. Ghosn, P. Sadate-Ngatchou, Y. Yang, L. A. Herzenberg, L. A. Herzenberg, Distinct progenitors for B-1 and B-2 cells are present in adult mouse spleen. Proc. Natl. Acad. Sci. U.S.A. 108, 2879-2884 (2011).
49. E. E. Ghosn, A. A. Cassado, G. R. Govoni, T. Fukuhara, Y. Yang, D. M. Monack, K. R. Bortoluci, S. R. Almeida, L. A. Herzenberg, L.A.Herzenberg, Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc. Natl. Acad. Sci. U.S.A. 107, 2568-2573 (2010).
50. A. Billiau, H. Heremans, F. Vandekerckhove, R. Dijkmans, H. Sobis, E. Meulepas, H. Carton, Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J. Immunol. 140, 1506-1510 (1988).
51. I. A. Ferber, S. Brocke, C. Taylor-Edwards, W. Ridgway, C. Dinisco, L. Steinman, D. Dalton, C. G. Fathman, Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156, 5-7 (1996).
52. M. Krakowski, T. Owens, Interferon-g confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 26, 1641-1646 (1996).
53. J. A. Voorthuis, B. M. Uitdehaag, C. J. De Groot, P. H. Goede, P. H. van der Meide, C. D. Dijkstra, Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats. Clin. Exp. Immunol. 81, 183-188 (1990).
54. D. O. Willenborg, S. A. Fordham, M. A. Staykova, I. A. Ramshaw, W. B. Cowden, IFN-γ is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: A possible role for nitric oxide. J. Immunol. 163, 5278-5286 (1999).
55. D. Games, D. Adams, R. Alessandrini, R. Barbour, P. Berthelette, C. Blackwell, T. Carr, J. Clemens, T. Donaldson, F. Gillespie, T. Guido, S. Hagopian, K. Johnson-Wood, K. Khan, M. Lee, P. Leibowitz, I. Lieberburg, S. Little, E. Masliah, L. McConlogue, M. Montoya-Zavala, L. Mucke, L. Paganini, E. Penniman, M. Power, D. Schenk, P. Seubert, B. Snyder, F. Soriano, H. Tan, J. Vitale, S.Wadsworth, B. Wolozin, J. Zhao, Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523-527 (1995).
56. M. B. Eisen, P. T. Spellman, P. O. Brown, D. Botstein, Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 95, 14863-14868 (1998).
57. S. A. Villeda, J. Luo, K. I. Mosher, B. Zou, M. Britschgi, G. Bieri, T. M. Stan, N. Fainberg, Z. Ding, A. Eggel, K. M. Lucin, E. Czirr, J. S. Park, S. Couillard-Després, L. Aigner, G. Li, E. R. Peskind, J. A. Kaye, J. F. Quinn, D. R. Galasko, X. S. Xie, T. A. Rando, T. Wyss-Coray, The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477, 90-94 (2011).
58. M. Pepper, M. K. Jenkins, Origins of CD4+ effector and central memory T cells. Nat. Immunol. 12, 467-471 (2011).
59. E. Check, Nerve inflammation halts trial for Alzheimer's drug. Nature 415, 462 (2002).
60. M. Roederer, Spectral compensation for flow cytometry: Visualization artifacts, limitations, and caveats. Cytometry 45, 194-205 (2001).